For example, dipeptidyl peptidase IV inhibitors [49, 50] and sodium-glucose cotransporter 2 inhibitors [51], which are currently the mainstream prescriptions in Japan, are unlikely to cause hypoglycemia by themselves, but it is reported that the combined use of sulfonylureas and insulin is more likely to cause hypoglycemia, and the guidelines also draw attention to this likelihood [34]. This evidence concerns the gene SLC5A2 and Hypoglycemia.